Table 1.
inibition of rRNA synthesis | ||
---|---|---|
transcription | processing | |
Alkylating agents: | ||
Melphalan* | + | - |
Cisplatin* | + | - |
Oxaliplatin* | + | - |
Cyclophosphamide 1 * | + | - |
Intercalating agents: | ||
Doxorubicin * | + | - |
Mitoxantrone * | + | - |
Actinomycin D * | + | - |
Mitomycin C | + | - |
Antimetabolites: | ||
Methotrexate * | + | - |
5-Fluorouracil | - | + |
Topoisomerase inhibitors: | ||
Camptothecin | - | + |
Etoposide* | - | + |
Kinase inhibitors: | ||
Flavopiridol* | - | + |
Roscovitine | - | + |
Rapamycin | + | - |
Proteasome inhibitors: | ||
Bortezomib* | - | + |
Translation inhibitors: | ||
Homoharringtonine* | - | + |
Mitosis inhibitors: | ||
Vinblastine* | - | + |
rRNA polymerase I inhibitors: | ||
CX-5461 2 * | + | - |
* drugs currently used or in clinical development for the treatment of lymphomas and leukemia
1 Cyclophosphamide is metabolized to acrolein, which is responsible for the inhibition of rRNA transcription [60, 61]
2 CX-5461 is in phase I clinical trial in patients with haematological malignancies and in phase I/II trial in patients with breast cancer